Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily vs twice-daily fosamprenavir + ritonavir with abacavir/lamivudine in antiretroviral-naïve HIV-1 infected adults
2006-005579-16Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fosamprenavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by GSK. Primary endpoint: Proportion of subjects with HIV-1 RNA <400 copies/mL over 48 weeks (ITT-E, TLOVR). Started Jan 2007; status: completed.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-005579-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005579-16.